[Multigene panel testing for tumors of known origin]

Luxardo R. Bardach A, Alfie V, Perelli L, Lazo E, Pichon Riviere A, García Marti S, Augustovski F, Ciapponi A, Alcaraz A
Record ID 32018012830
Spanish
Original Title: Paneles multigenéticos en tumores de origen conocido
Authors' recommendations: "Conclusions Low quality evidence suggests that the use of multigene panel testing in cancer of known etiology, specifically those inherited cancer predisposition syndromes, may have an uncertain net benefit since the efficacy of specific therapies associated to gene detection of multigene panel testing is unknown. No clinical practice guideline assessing the use of multigene panel testing for all types of cancers in general has been found. However, all the clinical practice guidelines for breast cancer recommend multigene panel testing in different situations, based on the patient and/or tumor characteristics. In the case of non-small cell lung cancer, there is no consensus among the guidelines on recommending multigene panel testing. The guidelines assessing colorectal cancer suggest offering multigene panel testing prior to initiating treatment. As regards prostate cancer, the guidelines agree on recommending genetic counselling, but there is no consensus on multigene panel testing. The health funders surveyed from the United States cover multigene panel testing for breast/ovarian cancer and in patients with primary tumors who may have an inherited syndrome. No cost-effectiveness study evaluating the use of multigene panel testing in all the types of cancer, in general, has been found. However, the United Kingdom considers that the technology is cost-effective in breast cancer; and economic evaluations from Spain and the United States on non-small cell lung cancer consider the use of multigene panel testing is potentially cost-effective. It is important to take into account that the results of a multigene panel testing may imply significant additional costs since it may require specific antineoplastic therapy. No economic evaluations have been found locally."
Details
Project Status: Completed
URL for project: https://ets.iecs.org.ar/publication/2101
Year Published: 2023
URL for published report: https://ets.iecs.org.ar/publication/2101
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Neoplasms
  • Neoplasms, Unknown Primary
  • Genetic Testing
  • High-Throughput Nucleotide Sequencing
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.